Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome
NCT ID: NCT02045654
Last Updated: 2014-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1 participants
OBSERVATIONAL
2014-01-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome
NCT04515914
A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
NCT02013102
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome
NCT01400633
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
NCT01751867
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
NCT00744757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Survival and response Analysis
* Response rate
* Overall survival
* Leukemia free survival
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MDS patients
MDS patients who were treated with decitabine
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Ho Jang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Ho Jang, Pf
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Hematology Oncology, Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-01-086
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.